|
TMPRSS-ERG fusion in men with prostate cancer (PCa) and non-prostate malignancies: Defining a role for comprehensive genomic profiling (CGP) to guide clinical care. |
|
|
|
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services |
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Medivation; Oncogenex |
Honoraria - Janssen Oncology; Medivation; Sanofi |
Consulting or Advisory Role - Janssen Oncology; Medivation; Millennium |
Speakers' Bureau - Janssen Oncology; Medivation; Sanofi |
Research Funding - Medivation |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Medivation; Sanofi |
|
|
Stock and Other Ownership Interests - Accelerated Medical Diagnostics; LP Therapeutics |
Consulting or Advisory Role - Novartis |
Research Funding - Abbott; Altor BioScience; Novartis |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
|
|
Employment - Foundation Medicine |